Loading
A phase 3 trial of Tretinoin, Mifepristone, Alitretinoin and Tamoxifen in Breast cancer, run by Mahmoud Ramadan mohamed Elkazzaz, with a status the registry has not verified recently.
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer is a phase 3 interventional study registered as NCT05016349 by Mahmoud Ramadan mohamed Elkazzaz, with 160 participants planned, started 2021-08 and due to reach its primary completion in 2021-10. Interventions recorded: All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone, Cannabidiol, 9 cis retinoic acid, Tamoxifen, Standard therapy. Conditions recorded: Breast Cancer Female.
Linked to the drug Alitretinoin because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mifepristone, Breast cancer (all types) and the tag pipeline.
Shares Mifepristone, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen and the tag pipeline.
Shares Tamoxifen and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/